<DOC>
	<DOC>NCT02537015</DOC>
	<brief_summary>This study evaluates the long-term (9-months) safety of the Bimatoprost Ocular Insert in subjects with Glaucoma or Ocular Hypertension. All the subjects will receive Bimatoprost Ocular Insert and will wear it for approximately 3 months (12 weeks), then will have a that Insert removed and a new Insert placed for another 24 weeks (approximately 6 months).</brief_summary>
	<brief_title>An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>1. Completed FSV5004 study. 2. Written informed consent prior to any study procedure. 3. Willingness to comply with the visit schedule. Key 1. Participation in an investigational drug or device study other than FSV5004 within the past 6 months or anticipated participation during the study period. 2. Subjects who will require contact lens use during the study period. 3. Any condition or situation (such as uncontrolled systemic disease) that, in the Investigator's opinion, might confound the results of the study, may put the subject at significant risk or might interfere with the subject's ability to participate in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>